Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness

View/ Open
Author
Yazdanpanah, Yazdan
Perelman, Julian
DiLorenzo, Madeline A.
Alves, Joana
Barros, Henrique
Mateus, Céu
Pereira, João
Mansinho, Kamal
Robine, Marion
Park, Ji-Eun
Ross, Eric L.
Noubary, Farzad
Paltiel, A. David
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1371/journal.pone.0084173Metadata
Show full item recordCitation
Yazdanpanah, Y., J. Perelman, M. A. DiLorenzo, J. Alves, H. Barros, C. Mateus, J. Pereira, et al. 2013. “Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness.” PLoS ONE 8 (12): e84173. doi:10.1371/journal.pone.0084173. http://dx.doi.org/10.1371/journal.pone.0084173.Abstract
Objective: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening. Design: We used Portuguese national clinical and economic data to conduct a model-based assessment. Methods: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292 cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental cost-effectiveness. Results: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months (QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of €28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for example screening annually in men who have sex with men or screening every three years in regions with higher incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively. Conclusions: One-time HIV screening in the Portuguese national population will increase survival and is cost-effective by international standards. More frequent screening in higher-risk regions and subpopulations is also justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk populations and geographic settings.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867470/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879235
Collections
- HMS Scholarly Articles [17852]
- SPH Scholarly Articles [6351]
Contact administrator regarding this item (to report mistakes or request changes)